The substantial downgrade in guidance from 45% - 55% to 10% - 15% 2017 top line growth is clearly very disappointing. We believe the decrease largely results from smaller than anticipated sample volumes and delays in a large Medicare-funded ConfirmMDx post-marketing study as well as contractual delays related to the flow of billable cases from one or more of its larger customers with whom it has service agreements. The company will provide a more detailed analysis and hopefully better guidance a ....
29 Dec 2017
Contractual delays drive downgrade
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Contractual delays drive downgrade
MDxHealth S.A. (0O8G:LON) | 0 0 0.3% | Mkt Cap: 168.5m
- Published:
29 Dec 2017 -
Author:
Chris Redhead -
Pages:
5
The substantial downgrade in guidance from 45% - 55% to 10% - 15% 2017 top line growth is clearly very disappointing. We believe the decrease largely results from smaller than anticipated sample volumes and delays in a large Medicare-funded ConfirmMDx post-marketing study as well as contractual delays related to the flow of billable cases from one or more of its larger customers with whom it has service agreements. The company will provide a more detailed analysis and hopefully better guidance a ....